A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)Erica Brivio, C. Michel Zwaan, Ingrid Øra et al.|Blood|2020Cited by 93
PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrumKaram Al-Halabi, Christine Haberler, Damian Stichel et al.|Acta Neuropathologica|2021Cited by 83
Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplificationMichaela‐Kristina Keck, Andreas von Deimling, David Jones et al.|Acta Neuropathologica|2022Cited by 44
A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 StudyErica Brivio, C. Michel Zwaan, Marta López‐Yurda et al.|Blood|2019Cited by 8
Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplificationMichaela‐Kristina Keck, Andreas von Deimling, Martin Sill et al.|Acta Neuropathologica|2023Cited by 4